


**IN THE CLAIMS:**

This listing of claims will replace all prior versions and listing of claims in the application.

**Listing of claims:**

Claim 1 (currently amended): A compound of formula (I):



(I)

wherein:

R<sup>1</sup> is halo, cyano, C<sub>1-3</sub>alkyl or C<sub>1-3</sub>alkoxy;

p is 0-2; wherein the values of R<sup>1</sup> may be the same or different;

R<sup>2</sup> is hydrogen, C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl, C<sub>2-4</sub>alkynyl, C<sub>3-6</sub>cycloalkyl, C<sub>3-6</sub>cycloalkylC<sub>1-3</sub>alkyl, a heterocyclyl or heterocyclylC<sub>1-3</sub>alkyl; wherein R<sup>2</sup> may be optionally substituted on carbon by one or more methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;

R<sup>3</sup> is hydrogen, halo or cyano;

R<sup>4</sup> is ~~C<sub>2-6</sub>alkyl~~-C<sub>1-6</sub>alkyl or C<sub>1-6</sub>alkoxyC<sub>1-6</sub>alkyl;

R<sup>5</sup> is C<sub>1-6</sub>alkyl or C<sub>2-6</sub>alkenyl; wherein R<sup>5</sup> may be optionally substituted on carbon by one or more methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy;

R<sup>6</sup> is ~~halo or~~ C<sub>1-4</sub>alkyl;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

with the proviso that if  $R^4$ ,  $R^5$  and  $R^6$  are all methyl then  $R^2$  is not hydrogen, optionally substituted  $C_{1-4}$ alkyl or  $C_{3-6}$ cycloalkyl.

Claim 2 (**currently amended**): The A-compound of formula (I) according to claim 1 wherein p is 0; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 3 (**currently amended**): The A-compound of formula (I) according to claim 1 or 2 wherein  $R^2$  is hydrogen; or  $C_{1-4}$ alkyl or heterocyclyl  $C_{1-3}$ alkyl; wherein  $R^2$  may be optionally substituted on carbon by one or more methoxy or ethoxy; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 4 (**currently amended**): The A-compound of formula (I) according to claim 1 ~~anyone of claims 1-3~~ wherein  $R^3$  is hydrogen or halo; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 5 (**currently amended**): The A-compound of formula (I) according to claim 1 ~~anyone of claims 1-4~~ wherein  $R^4$  is  $C_{2-4}$ alkyl- $C_{1-4}$ alkyl; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 6 (**currently amended**): The A-compound of formula (I) according to claim 1 ~~anyone of claims 1-5~~ wherein  $R^5$  is  $C_{1-6}$ alkyl; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 7 (**currently amended**): The A-compound of formula (I) according to claim 1 ~~anyone of claims 1-6~~ wherein  $R^6$  is methyl or halo; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 8 (**currently amended**): The A-compound of formula (I) according to claim 1 (as depicted in claim 1) wherein:

p is 0;

$R^2$  is hydrogen, 2-methoxyethyl, methyl, 3-methoxypropyl or 2-ethoxyethyl ~~or 2-pyrazol-1-ylethyl~~;

$R^3$  is hydrogen ~~or bromo~~;

$R^4$  is ~~methyl~~, ethyl or isopropyl;

$R^5$  is methyl or ethyl;

$R^6$  is methyl ~~or bromo~~;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

~~with the proviso that if  $R^4$ ,  $R^5$  and  $R^6$  are all methyl then  $R^2$  is not hydrogen, 2-methoxyethyl, methyl, 3-methoxypropyl or 2-ethoxyethyl.~~

Claim 9 (currently amended): The A-compound of formula (I) according to claim 1  
(~~as depicted in claim 1~~) selected from:

4-(1,2-diethyl-4-methylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}  
pyrimidine;

4-(1-ethyl-2,4-dimethylimidazol-5-yl)-2-{4-[N-(2-ethoxyethyl)sulphamoyl]anilino}  
pyrimidine;

4-(1-ethyl-2,4-dimethylimidazol-5-yl)-2-{4-[N-(3-methoxypropyl)sulphamoyl]anilino}  
pyrimidine;

4-(1-ethyl-2,4-dimethylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}  
pyrimidine;

4-(1-ethyl-2,4-dimethylimidazol-5-yl)-2-{4-[N-(methyl)sulphamoyl]anilino}pyrimidine;

4-(1-ethyl-2,4-dimethylimidazol-5-yl)-2-(4-sulphamoylanilino)pyrimidine;

4-(1-isopropyl-2,4-dimethylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}  
pyrimidine;

4-(1-isopropyl-2,4-dimethylimidazol-5-yl)-2-{4-[N-(3-methoxypropyl)sulphamoyl]anilino}  
pyrimidine;

4-(1-isopropyl-2,4-dimethylimidazol-5-yl)-2-(4-sulphamoylanilino)pyrimidine;

4-(1-isopropyl-2,4-dimethylimidazol-5-yl)-2-{4-[N-(2-ethoxyethyl)sulphamoyl]anilino}

pyrimidine; or

4-(1-isopropyl-2,4-dimethylimidazol-5-yl)-2-{4-[N-(methyl)sulphamoyl]anilino}pyrimidine;

4-(1,2,4-trimethylimidazol-5-yl)-2-{4-[N-(2-pyrazol-1-ylethyl)sulphamoyl]anilino}

pyrimidine; or


4-(4-bromo-1,2-dimethylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}

pyrimidine;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.


Claim 10 (**currently amended**): A process for preparing a compound of formula (I) or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof as claimed in claim 1, which process (wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and p are, unless otherwise specified, as defined in claim 1) comprises of:

Process a) reaction of a pyrimidine of formula (II):



(II)


wherein L is a displaceable group; with an aniline of formula (III):



(III)


or

Process b) reacting a compound of formula (IV):



(IV)


with a compound of formula (V):



(V)


wherein T is O or S;  $R^x$  may be the same or different and is  $C_{1-6}$ alkyl;

*Process c)* reacting a pyrimidine of formula (VI):



(VI)


wherein X is a displaceable group; with an amine of formula (VII):



(VII)


or

*Process d)* reacting a pyrimidine of formula (VIII)



(VIII)

with a compound of formula (IX):



(IX)

where Y is a displaceable group;

and thereafter, optionally if necessary:

- i) converting a compound of the formula (I) into another compound of the formula (I);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

Claim 11 (**currently amended**): A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, according to claim 1 ~~any one of claims 1-9~~, in association with a pharmaceutically-acceptable diluent or carrier.

Claim 12-21 (**cancelled**).

Claim 22 (**new**): A method for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula (I) or a

pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof as claimed in claim 1.

Claim 23 (**new**): A method for the inhibition of CDK2, CDK4 or CDK6 in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or *in-vivo* hydrolysable ester thereof as claimed in claim 1.

Claim 24 (**new**): A method of treating cancer in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or *in-vivo* hydrolysable ester thereof as claimed in claim 1.

Claim 25 (**new**): The method of claim 24 wherein said cancer is selected from leukaemia, breast cancer, lung cancer, colorectal cancer, stomach cancer, prostate cancer, bladder cancer, pancreatic cancer, ovarian cancer, liver cancer, kidney cancer, skin cancer and cancer of the vulva.